ABB  Vol.5 No.3 , February 2014
Activation of human monocytes/macrophages by OHR/AVR118 promotes both pro- and Anti-Inflammatory phenotypes
Abstract: The immunomodulator OHR/AVR118 has been shown to increase IL-8 and MCP-1 secretion from non-activated human monocytes and U937 pro-monocytic cells, but to decrease MCP-1 secretion from LPS-activated monocytes, suggesting its effect depends on immune cell environment and/or activation state. We therefore assessed the effect of OHR/AVR118 on cytokine secretion by human PBMCs and adherent monocytes. OHR/AVR118 increased IL-6, IL-1β, and TNF-α secretion byPHA/IL-2-primed PBMCs, but did not alter IL-12 secretion. In contrast, treatment of LPS-activated monocytes decreased TNF-α and IL-12, increased IL-6, but did not alter IL-1β, secretion. To further show that the effect of OHR/AVR118 depends on cellular environment, we monitored U937 differentiation towards mature macrophages in the presence of drug. OHR/AVR118 promoted a pro-inflammatory response in PMA-activated cells, as demonstrated by increased expression of the maturation markers CD86, CD32, and CD87 and by increased IL-8, MCP-1, and GM-CSF secretion. In undifferentiated U937 cells, OHR/AVR118 did not alter phagocytosis of opsonized S. aureus and IL-10 secretion. Whereas, after activation, OHR/AVR118 induced an anti-inflammatory phenotype, as indicated by reduced phagocytosis and increased IL-10 secretion. Overall, these findings suggest that OHR/AVR118 has a dual action on monocyte/macrophage function depending on cellular activation state, resulting in either further activation or suppression.
Cite this paper: Hirchman, S. (2014) Activation of human monocytes/macrophages by OHR/AVR118 promotes both pro- and Anti-Inflammatory phenotypes. Advances in Bioscience and Biotechnology, 5, 161-168. doi: 10.4236/abb.2014.53020.

[1]   Friedland, B., Hirschman, S.Z. and Taraporewala, I.B. (2005) Preparation of a therapeutic composition. US Patent No. 6,921,542.

[2]   Levett, P.N., Hirschman, S.Z., Roach, T.C., Broome, H., Alexander, R.J. and Fraser, H.S. (2002) Randomized, placebo-controlled trial of product R, a peptide-nucleic acid immunomodulator, in the treatment of adults infected with HIV. HIV Clinical Trials, 3, 272-278.

[3]   Olimpio, J.T., Hirschman, S.Z., Shtemer, Z. and Didiego, M. (2004) Anti-cachectic effects of a novel peptide-nucleic acid: preliminary results of a phase I/II clinical trial. Journal of Clinical Oncology, 22, 8087.

[4]   Chasen, M., Hirschman, S.Z. and Bhargava, R. (2012) Phase II study of the novel peptide nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. Journal of the American Medical Directors Association, 12, 62-67.

[5]   Lazzarino, D.A., de Diego, M., Hirschman, S.Z., Zhang, K.Y., Shaikh, S., Musi, E., Liaw, L., et al. (2001) IL-8 and MCP-1 secretion is enhanced by the peptide-nucleic acid immunomodulator, Product R, in U937 cells and primary human monocytes. Cytokine, 14, 234-239.

[6]   Mantovani, A., Schioppa, T., Biswas, S.K., Marchesi, F., Allavena, P. and Sica, A. (2003) Tumor-associated macrophages and dendritic cells as prototypic Type II polarized myeloid populations. Tumori, 89, 459-468.

[7]   Nagy, Z.S., Ross, J., Cheng, H., Stepkowski, S.M. and Kirken, R.A. (2004) Regulation of lymphoid cell apoptosis by Jaks and Stats. Critical Reviews in Immunology, 24, 87-110.

[8]   Hirschman, S.Z. and Chen, C.W. (1996) Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus. Journal of Investigative Medicine, 44, 347-351.

[9]   Lazzarino, D.A., De Diego, M., Musi, E., Hirschman, S.Z. and Alexander, R.J. (2000) CCR5 and CXCR4 expression by H9 T-cells is downregulated by a peptide-nucleic acid immunomodulator. Immunology Letters, 74, 189-195.

[10]   Navarro, S., Debili, N., Bernaudin, J.F., Vainchenker, W. and Doly, J. (1989) Regulation of the expression of IL-6 in human monocytes. The Journal of Immunology, 142, 4339-4345.

[11]   Elias, J.A., Schreiber, A.D., Gustilo, K., Chien, P., Rossman, M.D., Lammie, P.J., et al. (1985) Differential interleukin 1 elaboration by unfractionated and density fractionated human alveolar macrophages and blood monocytes: Relationship to cell maturity. The Journal of Immunology, 135, 3198-3204.

[12]   Sallerfors, B. and Olofsson, T. (1992) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by adherent monocytes measured by quantitative immunoassays. European Journal of Haematology, 49, 199-207.

[13]   Agarwal, S., Piesco, N.P., Johns, L.P. and Riccelli, A.E. (1995) Differential expression of IL-1 beta, TNF-alpha, IL-6, and IL-8 in human monocytes in response to lipopolysaccharides from different microbes. Journal of Dental Research, 74, 1057-1065.

[14]   Hayes, M.P., Wang, J. and Norcross, M.A. (1995) Regulation of interleukin-12 expression in human monocytes: Selective priming by interferon gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood, 86, 646-650.

[15]   Morrissette, N., Gold, E. and Aderem, A. (1999) The macrophage—A cell for all seasons. Trends in Cell Biology, 9, 199-201.

[16]   Duffield, J.S. (2003) The inflammatory macrophage: A story of Jekyll and Hyde. Clinical Science, 104, 27-38.

[17]   Goerdt, S., Politz, O., Schledzewski, K., Birk, R., Gratchev, A., Guillot, P., et al. (1999) Alternative versus classical activation of macrophages. Pathobiology, 67, 222-226.

[18]   Mantovani, A., Sozzani, S., Locati, M., Allavena, P. and Sica, A. (2002) Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 23, 549-555.

[19]   Leibson, P.J. (2004) The regulation of lymphocyte activation by inhibitory receptors. Current Opinion in Immunology, 16, 328-336.

[20]   Kildsgaard, J., Hollmann, T.J., Matthews, K.W., Bian, K., Murad, F. and Wetsel, R.A. (2000) Cutting edge: Targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. The Journal of Immunology, 165, 5406-5409.

[21]   Krakauer, T., Vilcek, F. and Oppenheim, J.J. (1999) Proinflammatory chemokines. TNF and IL-1 families, chemokines, TGF-beta, and others. In: Paul, W.E., Ed., Fundamental Immunology, 4th Edition, Lippincott-Raven Publishers, Philadelphia, 775-811.

[22]   Greenberg, S. and Grinstein, S. (2002) Phagocytosis and innate immunity. Current Opinion in Immunology, 14, 136-145.

[23]   Taylor, P.R., Martinez-Pomares, L., Stacey, M., Lin, H.H., Brown, G.D. and Gordon, S. (2005) Macrophage receptors and immune recognition. Annual Review of Immunology, 23, 901-944.

[24]   Hunter, S., Indik, Z.K., Kim, M.K., Cauley, M.D., Park, J.G. and Schreiber, A.D. (1998) Inhibition of Fcgamma receptor-mediated phagocytosis by a nonphagocytic Fcgamma receptor. Blood, 91, 1762-1768.

[25]   Clynes, R., Maizes, J.S., Guinarmard, R., Ono, M., Takai, T. and Ravetch, J.V. (1999) Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. The Journal of Experimental Medicine, 189, 179-185.

[26]   Wijngaarden, S., van de Winkel, J.G., Jacobs, K.M., Nijlsma, J.W., Lafeber, F.P. and van Roon, J.A. (2004) A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis & Rheumatology, 50, 3878-3887.

[27]   Fukuyama, H., Nimmerjahn, F. and Ravetch, J.V. (2005) The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nature Immunology, 6, 99-106.

[28]   Bright, J.J., Musuro, B.F., Du, C. and Sriram, S. (1998) Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. Journal of Neuroimmunology, 82, 22-30.

[29]   Ortmann, R.A. and Shevach, E.M. (2001) Susceptibility to collagen-induced arthritis: Cytokine-mediated regulation. Clinical Immunology, 98, 109-118.

[30]   Cavaillon, J.M. (1994) Cytokines and macrophages. Biomedicine & Pharmacotherapy, 48, 445-453.